期刊文献+

用循证医学方法分析我国Vogt-小柳-原田综合征的特点 被引量:6

Analysis of the characteristics of Vogt-Koyanagi-Harada syndrome by evidence-based medicine method
下载PDF
导出
摘要 Vogt-小柳-原田综合征是一种常见的疾病。我们对42篇文献(含1589例)进行分析整理,结果本病发病年龄8~76(平均36.03)岁。男835例,女736例。双眼同时或先后发病1585例,4例为单眼发病。发病时视力半数<0.2,也有少部分接近正常。眼外损害以头痛最常见,约为67%,耳鸣和脱发的发生率分别为39%和33%。也有相当部分患者并未出现任何眼外症状。眼底荧光血管造影是最重要检查,主要表现为斑驳状高荧光,视盘染色和多湖样视网膜下染料积存。所有患者均采用激素治疗,复发病例部分加用了免疫抑制。经过治疗,有超过3/4的患者视力保持在0.6以上,超过半数的患者可以获得1.0以上的视力。系统治疗的患者复发率较低。白内障和青光眼是本病的主要并发症,发生率为20%和9%。 Vogt-Koyanagi-Harada (VKH) syndrome is a common disease. 42 papers containing a total of 1 589 cases shown that obtained. Age of onset in patients with VKH syndrome varied from 8 to 76 (average age 36). Male were 835, and female were 736. Patients whose binoculus involved in VKH syndrome at the same time or in succession were 1 585 and monocular incidence was in 4 cases. Headache was noted in 67% of these patients. Tinnitus and alopecia were noted in 39% and 33%. Before the treatment, patients of visual acuity 〈 0.2 were found to be 50%, and few was close to normal. Fundus fluorescein angiography (FFA) is the most important examination, its main performance were mottled hyper- fluorescence; optic disc dyeing and cystic fluorescein reservoir. Corticosteroid were used in all cases. Some cases added immune agents. After treatment. Visual acuity ≥0.6 were found in 76%, and ≥0.1 were more than 50%. Relapse incidence (RI) of systemic therapy was lower. Cataract and glaucoma were the main complications, and incidence rate was nearly 20% and 9%.
作者 赵桂玲
出处 《国际眼科杂志》 CAS 2009年第7期1401-1403,共3页 International Eye Science
关键词 VOGT-小柳-原田综合征 循证医学 诊断标准 Vogt-Koyanagi-Harada syndrome evidence- based medicine diagnostic criteria
  • 相关文献

参考文献41

二级参考文献117

共引文献134

同被引文献17

  • 1常建民,石超,傅裕.Vogt-小柳-原田综合征[J].临床皮肤科杂志,2007,36(6):373-374. 被引量:2
  • 2Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthahnol Clin, 2006, 46:111-122.
  • 3Damico FM, Cunha-Ne E, Goldberg AC, et al. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with Vogt-Koyanagi-Harada uveitis. Invest Ophthalmol Vis Sci, 2005,46 : 2465 -2471.
  • 4Dolz-Marco R, Gallego-Pinazo R, Diaz-l.lopis M. Rituximab in refractory Vogt-Koyanagi-Harada disease. J Ophthalmic lnflamm Infect, 2011 , 1:177-180.
  • 5Paredes 1, Ahmed M, Foster CS, et al. lmmunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul lmmunol lnflamm, 2006, 14:87-90.
  • 6Xianglong Yi’Peizeng Yang,Min Sun,et al. Decreased 1,25-Di-hydroxyvitamin D3 level is involved in the pathogenesis ofVogt-Koyanagi-Harada (VKH) disease [J]. Molecular Vision,2011,17:673-679.
  • 7Gohdo T, Tsukahara S. Ultrasound biomicroscopy of shallow an-terior chamber in V ogt-Koy anagi-Harada syndrome [J].Am JOphthalmol, 1996,122:112-2-114.
  • 8Read RW,Holland GN,Rao NA,et al. Revised diagnostic criteriafor Vogl-Koyanagi-Harada disease:report of an international cornmi ttee*on nomenclature[J]. Am J Ophthalmol,2001,131:647-652.
  • 9Guenoun JM,Larte C,Dhote R,et al. Vogt-Koyanagi-Haradadisease:clinical features,therapy and long-term visual outcome in aCaucasian and African population[J]. J Fr.Ophta.lmol,2004,27:1013-1016.
  • 10Soheilian M,Aletaha M,Yazdani S,et al. Management of pediatricVogt-Koyanagi-Harada( VKH )-associated panuveitis [J]. OculImmunol lnfiarnm,2006,14:91-98.

引证文献6

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部